With the acquisition of surgical technology company Visualase, Medtronic is further bolstering one of its own fastest growing segments--as well as a large and fast growing group for Covidien. Medtronic expects to complete its $42.9 billion acquisition of Covidien by early 2015.
The Medtronic merger with Covidien could offer a particular threat to C.R. Bard's vascular business--its largest segment and one of its fastest growing. The company was clear that it's actively in the market for its own strategic acquisitions; it hasn't disclosed a sizeable deal in almost a year.
Covidien is celebrating third quarter earnings buoyed by strong sales, with its surgical solutions unit and progress in emerging markets generating an sizeable increase in cash flow.
Catheter-directed thrombolysis (CDT) has been used in an effort to reduce the incidence of post-thrombotic syndrome in deep vein thrombosis. But a newly published observational study suggests that not only is catheter use ineffective at preventing post-thrombotic syndrome, but it is actually associated with higher rates of adverse events.
As Covidien strides into a merger with Medtronic, the company last week announced the appointment of Bill Burke as CFO for Covidien Europe.
Hiring ahead of and cutting after mergers is always tricky, but organizational change marches on. Post-merger Johnson & Johnson and pre-merger Covidien are both forging ahead, with cuts in J&J's DePuy Synthes and hiring for Covidien.
The president of Covidien's $1.6 billion vascular product group said that the impending merger with Medtronic was necessary from her perspective because being "a vascular player without cardiovascular, I think long term that would have been a real issue.
The leader of the looming integration effort facing Medtronic and Covidien stressed "balance sheet flexibility" as one of the main drivers of the $43 billion mega deal, and said it will lead to more M&A activity in early stage companies, although some investors disagree.
Medtronic is stirring the U.S. tax pot with its announcement of an acquisition of Ireland-based company, Covidien. The acquisition would make Medtronic a foreign-based company, releasing it from U.S. tax laws and saving the company $3.5 to $4.2 billion annually.
The FDA slapped its most severe label on Nitinol Devices & Components' recalled HydroFinity Hydrophilic Guidewires, meaning the agency believes "there is a reasonable probability that use of these products will cause serious adverse health consequences or death."